Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0000950170-25-075979

Chief R&D Officer sold 10,712 shares at $0.67 ($7,177)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-05-19 Sale : show line 1 in the form −10,712 $0.67 $7,177 305,892 D
Open-market sales · 10,712 sh · avg $0.67 · $7,177
Loading xslF345X05/ownership.xml…